EHA 2022 – Naval Daver

Naval Daver overviews the most promising new agents in the treatment of AML, how existing drugs can blend into new regimens and how the prognosis of patients with AML will evolve in the years to come. Finally, he talks about risk factors for ICI-related pneumonitis development and if pneumonitis increases mortality in AML patients.

Here is the full EHA 2022 report.